Background
GPR103 is a G-protein coupled receptor that has been shown to be expressed primarily in brain, heart, kidney, adrenal gland, retina and testis. Its ligand has been identified as a 43-residue RF-amide peptide known as QRFP. When administered centrally in mice, QRFP was shown to increase feeding, behavioral arousal and blood pressure. When administered iv, this peptide caused release of aldosterone. Knockout mice (GPR103 -/-) have suggested a role of GPR103 in regulating bone formation. These diverse but important physiological functions of this receptor and ligand make them important possible targets for drug discovery in several fields.
| General Info | |
| Synonyms | SP9155, AQ27 |
|---|---|
| Product Description | Human GPR103 Receptor-expressing GPCR (G protein-coupled receptor) stable, replicating cell line. |
| Target Type | GPCR |
| Product Type | Replicating Cell Line |
| Receptor | RFamide peptide |
| Sub-Type | GPR103 |
| Therapeutic Area | metabolic & gastrointestinal |
| Related Services | Membrane Preparation, Large-scale Cryopreservation, GPCR Screening |
| Genbank Accession Number | AF411117 |
| Validated Assay/Platform | calcium |
| References | Jiang, Y., Luo, L., et al., (2003) Identification and Charcterization of a Novel RF-amide Peptide Ligand for Orphan G-protein-coupled Receptor SP9155. J. Biol. Chem. 278: 27652-27657. Takayasu, S., Sakurai, T., et al., (2006) A neuropeptide ligand |
| Host cell | CHO-K1 |
| Mycoplasma Status | Negative (MycoAlert Kit) |
| Growth media | Ham's F12, 10% FBS, 1% NEAA, 400 µg/mL G418 |
| Storage & Packaging | |
| Packaging | Cryopreserved cells, 6 million cells per vial |
| Storage Recommendation | liquid nitrogen |
| Stability | At least 6 passages |
| Quantity | 6 million cells |
| Representative Screening Information | |
| Cell Line | CHO-K1 stably expressing human GPR103 QRFP receptor |
| Screening Assay | calcium mobilization assay |
| Readout | calcium sensitive fluorescent dye |
| Plate Format | 384 well |
| Instrument | FlexStation-III |
| Signal Window | 22.00 |
| Z Score | 0.85 |
| DMSO Tolerance | 1.0% DMSO |
| Testing Modes | agonist, antagonist |
| Testing Options | 16-point minimum, 4-point DRC (n = 4), 8-point DRC (n=3 or 4) |
| Turnaround Time | 2 weeks following receipt of Test Articles |
| Product Documentation | |
| Specification Sheet | |
| Screening Info | |



